Carl H. June
#17,354
Most Influential Person Now
American immunologist
Carl H. June's AcademicInfluence.com Rankings
Carl H. Junebiology Degrees
Biology
#598
World Rank
#1054
Historical Rank
#335
USA Rank
Immunology
#21
World Rank
#24
Historical Rank
#9
USA Rank
Download Badge
Biology
Carl H. June's Degrees
- Bachelors Biophysics Johns Hopkins University
- Masters Medicine Tufts University
Why Is Carl H. June Influential?
(Suggest an Edit or Addition)According to Wikipedia, Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research on T cell therapies for the treatment of several forms of cancers. In 2020 he was elected to the American Philosophical Society.
Carl H. June's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Chimeric antigen receptor T cells for sustained remissions in leukemia. (2014) (4010)
- Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. (2011) (2993)
- Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia (2018) (2931)
- Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. (2013) (2847)
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (2011) (2173)
- CAR T cell immunotherapy for human cancer (2018) (1527)
- A human memory T-cell subset with stem cell-like properties (2011) (1505)
- Cytokine release syndrome in severe COVID-19 (2020) (1486)
- The B7 and CD28 receptor families. (1994) (1405)
- CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. (1995) (1376)
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (2015) (1326)
- The CD28 signaling pathway regulates glucose metabolism. (2002) (1237)
- Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. (2014) (1231)
- Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. (2001) (1197)
- Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas (2017) (1126)
- Chimeric Antigen Receptor Therapy. (2018) (1122)
- Delivery technologies for cancer immunotherapy (2019) (1091)
- SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 (2004) (1074)
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma (2017) (1047)
- Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases (2008) (1010)
- Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. (2011) (1002)
- Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. (2009) (985)
- Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. (1989) (951)
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. (2013) (896)
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia (2018) (880)
- Engineered T cells: the promise and challenges of cancer immunotherapy (2016) (803)
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains (2009) (772)
- The Principles of Engineering Immune Cells to Treat Cancer (2017) (741)
- Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1 (2002) (740)
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. (2016) (730)
- NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma (2015) (696)
- CRISPR-engineered T cells in patients with refractory cancer (2020) (685)
- CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. (1989) (683)
- Role of the CD28 receptor in T-cell activation. (1990) (665)
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies (2013) (665)
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. (2016) (660)
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition (2016) (598)
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies. (2014) (576)
- Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells (2012) (575)
- Cytokine Storm (2020) (565)
- T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression (1987) (564)
- Adoptive T cell therapy for cancer in the clinic. (2007) (545)
- Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells (2013) (521)
- Gene transfer in humans using a conditionally replicating lentiviral vector (2006) (498)
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. (2015) (487)
- Human chimeric antigen receptor macrophages for cancer immunotherapy (2020) (469)
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells (2018) (466)
- Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction. (1990) (454)
- Isolation of a new herpesvirus from human CD4+ T cells. (1990) (448)
- Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB (2002) (443)
- Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. (2013) (438)
- Human T regulatory cell therapy: take a billion or so and call me in the morning. (2009) (438)
- Human naive and memory T lymphocytes differ in telomeric length and replicative potential. (1995) (437)
- Regulated expression of telomerase activity in human T lymphocyte development and activation (1996) (424)
- Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor (2011) (421)
- Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. (2016) (412)
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. (2016) (409)
- B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. (2019) (404)
- Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. (2010) (389)
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma (2015) (382)
- L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. (2004) (382)
- Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. (2000) (382)
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. (2014) (382)
- The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells (2011) (376)
- Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation. (1990) (374)
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell (2018) (374)
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans (2013) (371)
- Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. (2015) (365)
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. (2016) (359)
- PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. (2017) (358)
- Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. (1997) (356)
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. (2016) (351)
- Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity (2013) (350)
- Massive ex Vivo Expansion of Human Natural Regulatory T Cells (Tregs) with Minimal Loss of in Vivo Functional Activity (2011) (347)
- Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. (2018) (340)
- Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of indo-1 and immunofluorescence with flow cytometry. (1986) (327)
- Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. (2015) (326)
- Chimeric antigen receptor therapy for cancer. (2014) (325)
- Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors (2002) (325)
- Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. (2018) (324)
- Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors (2014) (322)
- The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. (2005) (319)
- Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia (2017) (315)
- Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. (2016) (312)
- Is autoimmunity the Achilles' heel of cancer immunotherapy? (2017) (310)
- In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. (2004) (310)
- ASSOCIATION BETWEEN CYCLOSPORIN NEUROTOXICITY AND HYPOMAGNESAEMIA (1984) (308)
- Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. (2004) (307)
- Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer (2005) (306)
- Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells (2003) (302)
- Adoptive cellular therapy: A race to the finish line (2015) (300)
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia (2015) (299)
- An inducible cytoplasmic factor (AU-B) binds selectively to AUUUA multimers in the 3' untranslated region of lymphokine mRNA (1991) (294)
- Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies (2015) (291)
- A versatile system for rapid multiplex genome-edited CAR T cell generation (2017) (290)
- Targeting Cardiac Fibrosis with Engineered T cells (2019) (287)
- Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo (2013) (283)
- Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. (1998) (280)
- A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. (2002) (274)
- ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. (2014) (272)
- Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18 (2017) (268)
- CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. (1996) (268)
- Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. (2018) (266)
- Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. (2010) (264)
- Principles of adoptive T cell cancer therapy. (2007) (264)
- Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. (2007) (263)
- Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor (2008) (259)
- In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). (2011) (258)
- Adoptive immunotherapy for cancer or viruses. (2014) (255)
- Genetic therapies against HIV (2007) (254)
- Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer (2018) (251)
- Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. (2007) (249)
- cis-acting sequences required for inducible interleukin-2 enhancer function bind a novel Ets-related protein, Elf-1 (1992) (247)
- The Inducible Costimulator (ICOS) Is Critical for the Development of Human TH17 Cells (2010) (247)
- Monoclonal TCR-redirected tumor cell killing (2012) (246)
- Ibrutinib treatment improves T cell number and function in CLL patients (2017) (244)
- Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. (1999) (244)
- Antiviral Effect and Ex Vivo CD4+ T Cell Proliferation in HIV-Positive Patients as a Result of CD28 Costimulation (1996) (233)
- Radiation and immunotherapy: a synergistic combination. (2013) (233)
- Emerging Cellular Therapies for Cancer. (2019) (231)
- Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. (1997) (227)
- The NFAT-1 DNA binding complex in activated T cells contains Fra-1 and JunB (1993) (227)
- Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. (2017) (226)
- Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer (2017) (225)
- Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells (2015) (225)
- Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. (1995) (223)
- A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. (2006) (221)
- Generation and Large‐Scale Expansion of Human Inducible Regulatory T Cells That Suppress Graft‐Versus‐Host Disease (2011) (218)
- Driving gene-engineered T cell immunotherapy of cancer (2016) (218)
- Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy (2016) (217)
- Cd40 Ligand (Cd154) Triggers a Short-Term Cd4+ T Cell Activation Response That Results in Secretion of Immunomodulatory Cytokines and Apoptosis (2000) (217)
- Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade (2019) (214)
- Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging (1997) (204)
- Engineering lymphocyte subsets: tools, trials and tribulations (2009) (200)
- 4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy1 (2007) (199)
- Ionizable Lipid Nanoparticle Mediated mRNA Delivery for Human CAR T Cell Engineering. (2020) (198)
- Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies (2020) (192)
- Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes. (1987) (190)
- A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. (1986) (190)
- CAR T cells produced in vivo to treat cardiac injury (2022) (188)
- PI 3-kinase: a pivotal pathway in T-cell activation? (1996) (186)
- Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection (2002) (184)
- Cutting Edge: Foxp3-Mediated Induction of Pim 2 Allows Human T Regulatory Cells to Preferentially Expand in Rapamycin1 (2008) (183)
- Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. (2003) (183)
- Lipopolysaccharide-induced protein tyrosine phosphorylation in human macrophages is mediated by CD14. (1993) (182)
- Treatment of advanced leukemia in mice with mRNA engineered T cells. (2011) (180)
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer (2017) (178)
- CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. (1990) (178)
- CD28 and Inducible Costimulatory Protein Src Homology 2 Binding Domains Show Distinct Regulation of Phosphatidylinositol 3-Kinase, Bcl-xL, and IL-2 Expression in Primary Human CD4 T Lymphocytes 1 (2003) (176)
- Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. (1995) (174)
- CD28 ligation in T-cell activation: evidence for two signal transduction pathways. (1990) (174)
- CD28 Costimulation Is Essential for Human T Regulatory Expansion and Function1 (2008) (174)
- Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. (1986) (168)
- Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. (2016) (168)
- IgE secretion by Epstein-Barr virus-infected purified human B lymphocytes is stimulated by interleukin 4 and suppressed by interferon gamma. (1989) (167)
- Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division. (1995) (167)
- Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager (2018) (165)
- Decade-long leukaemia remissions with persistence of CD4+ CAR T cells (2022) (164)
- CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges (2018) (161)
- Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. (2005) (161)
- Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. (2018) (160)
- Signal transduction through cd4 receptors: stimulatory vs. inhibitory activity is regulated by cd4 proximity to the cd31t cell receptor (1988) (156)
- Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. (2011) (156)
- Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. (2019) (154)
- CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. (1995) (153)
- Defining the critical hurdles in cancer immunotherapy (2011) (152)
- AU RNA-binding factors differ in their binding specificities and affinities. (1992) (151)
- Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance (2018) (150)
- CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. (2004) (150)
- Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. (2016) (147)
- 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. (2010) (147)
- Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology (2018) (147)
- The B 7 and CD 28 receptor families (147)
- Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. (2009) (147)
- A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses (2007) (145)
- Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street (2015) (145)
- The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma (2016) (145)
- Engineering HIV-Resistant Human CD4+ T Cells with CXCR4-Specific Zinc-Finger Nucleases (2011) (144)
- Distinct signal transduction in mouse CD4+ and CD8+ splenic T cells after CD28 receptor ligation. (1995) (143)
- Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer (2013) (143)
- Monoclonal antibody-defined functional epitopes on the adhesion-promoting glycoprotein complex (CDw18) of human neutrophils. (1986) (143)
- ICOS Costimulation Requires IL-2 and Can Be Prevented by CTLA-4 Engagement1 (2001) (142)
- Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. (2008) (142)
- Reciprocal expression of human ETS1 and ETS2 genes during T-cell activation: regulatory role for the protooncogene ETS1. (1990) (142)
- Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells (2018) (139)
- Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. (2014) (139)
- Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. (1999) (138)
- Cutting Edge: CTLA-4 Ligation Delivers a Unique Signal to Resting Human CD4 T Cells That Inhibits Interleukin-2 Secretion but Allows Bcl-XL Induction (1998) (137)
- Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. (2009) (135)
- Telomere Length, Telomerase Activity, and Replicative Potential in HIV Infection: Analysis of CD4+ and CD8+T Cells from HIV-discordant Monozygotic Twins (1997) (135)
- Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. (2004) (135)
- Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. (2008) (133)
- Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia (2018) (132)
- CD28 activation promotes Th2 subset differentiation by human CD4+ cells (1995) (132)
- Tat-functionalized near-infrared emissive polymersomes for dendritic cell labeling. (2007) (130)
- Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction. (2020) (130)
- Mesothelin, a novel immunotherapy target for triple negative breast cancer (2012) (130)
- Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. (1998) (130)
- Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor‐mediated activation (1989) (128)
- Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019) (2015) (128)
- Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. (2017) (128)
- Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation. (1986) (127)
- Inhibition of T cell receptor expression and function in immature CD4+CD8+ cells by CD4. (1990) (127)
- Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. (2016) (126)
- Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. (1998) (125)
- Regulation of TCR signaling by CD45 lacking transmembrane and extracellular domains. (1993) (122)
- Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. (2018) (116)
- CARs on track in the clinic. (2011) (116)
- An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation. (1991) (116)
- Evidence for the involvement of three distinct signals in the induction of IL-2 gene expression in human T lymphocytes. (1989) (116)
- Regulation of telomerase RNA template expression in human T lymphocyte development and activation. (1997) (116)
- IL-5 induces a Pgp-1 (CD44) bright B cell subpopulation that is highly enriched in proliferative and Ig secretory activity and binds to hyaluronate. (1990) (116)
- Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. (2017) (115)
- Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. (2019) (113)
- Evidence for Distinct Intracellular Signaling Pathways in CD34+ Progenitor to Dendritic Cell Differentiation from a Human Cell Line Model (1999) (113)
- Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy. (2017) (112)
- Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma (2005) (112)
- Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. (2004) (111)
- HIV-1-infected T cells show a selective signaling defect after perturbation of CD3/antigen receptor. (1988) (111)
- Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells (1992) (111)
- Costimulation of T cell receptor/CD3-mediated activation of resting human CD4+ T cells by leukocyte function-associated antigen-1 ligand intercellular cell adhesion molecule-1 involves prolonged inositol phospholipid hydrolysis and sustained increase of intracellular Ca2+ levels. (1992) (111)
- CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. (2019) (110)
- Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. (2013) (110)
- Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission (2012) (110)
- Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. (2013) (109)
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. (2016) (107)
- Regulatory CD 4 1 CD 25 1 T Cells in Tumors from Patients with Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer 1 (2001) (107)
- Clinical application of expanded CD4+25+ cells. (2006) (106)
- Engineered T cells for cancer therapy (2014) (106)
- A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-β Gene Transfer for Mesothelioma and Metastatic Pleural Effusions. (2010) (106)
- Clinical perspectives for regulatory T cells in transplantation tolerance. (2011) (105)
- Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells (2013) (104)
- Nanomaterials for T-cell cancer immunotherapy (2021) (104)
- Critical Requirement for the Membrane-Proximal Cytosolic Tyrosine Residue for CD28-Mediated Costimulation In Vivo1 (2001) (103)
- The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations (2018) (103)
- Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. (2005) (103)
- Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. (2013) (102)
- T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. (2013) (100)
- A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. (2002) (100)
- TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. (2003) (100)
- Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas (2018) (99)
- Multiple mechanisms regulate c‐myc gene expression during normal T cell activation. (1988) (97)
- CAR T-Cell Therapies in Glioblastoma: A First Look (2017) (97)
- Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12. (2018) (97)
- CD5 antibodies increase intracellular ionized calcium concentration in T cells. (1987) (94)
- CD40 ligand/CD40 stimulation regulates the production of IFN-gamma from human peripheral blood mononuclear cells in an IL-12- and/or CD28-dependent manner. (1998) (93)
- Rapid Immune Recovery and Graft-versus-Host Disease–like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells (2009) (93)
- Optimization of the PiggyBac Transposon System for the Sustained Genetic Modification of Human T Lymphocytes (2009) (93)
- Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. (2014) (92)
- Patient monitoring and follow‐up in lentiviral clinical trials (2013) (91)
- Regulatory T Cells and Human Myeloid Dendritic Cells Promote Tolerance via Programmed Death Ligand-1 (2010) (91)
- CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction. (1998) (91)
- Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy. (2018) (90)
- Chimeric Antigen Receptor Therapy for B-cell Malignancies (2011) (90)
- Chemokine receptor 5 knockout strategies (2011) (90)
- Productive Infection of Neonatal CD8+ T Lymphocytes by HIV-1 (1998) (89)
- Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms (2017) (89)
- Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells. (2000) (89)
- Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia (2018) (89)
- Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. (2013) (89)
- Single residue in CD28-costimulated CAR T cells limits long-term persistence and antitumor durability. (2020) (88)
- CD28‐deficient mice generate an impaired Th2 response to Schistosoma mansoni infection (1996) (88)
- Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors (2012) (88)
- A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma. (2011) (88)
- Distinct patterns of transmembrane calcium flux and intracellular calcium mobilization after differentiation antigen cluster 2 (E rosette receptor) or 3 (T3) stimulation of human lymphocytes. (1986) (86)
- Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. (2017) (86)
- A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. (2010) (86)
- T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. (2019) (86)
- Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging. (2000) (86)
- Activation of tyrosine phosphorylation in human T cells via the CD2 pathway. Regulation by the CD45 tyrosine phosphatase. (1990) (85)
- Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts (2013) (85)
- Transforming Growth Factor-β Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers (2008) (84)
- CD28 dependence of T cell differentiation to IL-4 production varies with the particular type 2 immune response. (1997) (83)
- Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation. (1997) (83)
- Protection against lethal toxic shock by targeted disruption of the CD28 gene (1996) (83)
- T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. (1999) (82)
- Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion. (1995) (81)
- The genomic organization of the CD28 gene. Implications for the regulation of CD28 mRNA expression and heterogeneity. (1990) (81)
- 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling (2020) (81)
- Phorbol esters induce differentiation of human CD34+ hemopoietic progenitors to dendritic cells: evidence for protein kinase C-mediated signaling. (1998) (80)
- Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. (2018) (80)
- Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration. (1990) (79)
- No T-cell tyrosine protein kinase signalling or calcium mobilization after CD4 association with HIV-1 or HIV-1 gp120 (1990) (79)
- PROFOUND HYPOMAGNESEMIA AND RENAL MAGNESIUM WASTING ASSOCIATED WITH THE USE OF CYCLOSPORINE FOR MARROW TRANSPLANTATION (1985) (78)
- In vivo calcium elevations in thymocytes with T cell receptors that are specific for self ligands. (1992) (78)
- Naı̈ve and Memory CD4 T Cells Differ in Their Susceptibilities to Human Immunodeficiency Virus Type 1 Infection following CD28 Costimulation: Implications for Transmission and Pathogenesis (1998) (77)
- Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients (1998) (77)
- Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas (2015) (76)
- Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells (2019) (75)
- CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995. 3: 87-98. (2010) (74)
- Bi-specific and Split CAR T Cells Targeting CD13 and TIM3 Eradicate Acute Myeloid Leukemia. (2020) (74)
- The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL). (2017) (73)
- Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL (2013) (73)
- Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (2016) (73)
- HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. (2003) (73)
- An NK-like CAR T cell transition in CAR T cell dysfunction (2021) (73)
- The CD45 tyrosine phosphatase regulates phosphotyrosine homeostasis and its loss reveals a novel pattern of late T cell receptor-induced Ca2+ oscillations (1992) (72)
- Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer. (2013) (72)
- Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate (2018) (72)
- IL-21 promotes the expansion of CD27+CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells (2013) (72)
- Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma (2007) (72)
- Ultrasonography and computed tomography in severe urinary tract infection. (1985) (71)
- Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. (2011) (71)
- B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study (2016) (70)
- Induction of calcium flux and enhancement of cytolytic activity in natural killer cells by cross-linking of the sheep erythrocyte binding protein (CD2) and the Fc-receptor (CD16). (1987) (70)
- Adoptive transfer of simian immunodeficiency virus (SIV) naïve autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status. (2002) (69)
- Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. (2018) (69)
- Genetic engineering of T cells for adoptive immunotherapy (2008) (68)
- Modulation of Susceptibility to HIV-1 Infection by the Cytotoxic T Lymphocyte Antigen 4 Costimulatory Molecule (2000) (68)
- CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells (2018) (68)
- Inflammatory cytokines IFN-gamma plus TNF-alpha induce regulated expression of CD80 (B7-1) but not CD86 (B7-2) on murine fibroblasts. (1997) (67)
- Driving cars to the clinic for solid tumors (2018) (67)
- Cancer immunotherapy comes of age and looks for maturity (2020) (67)
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials (2016) (67)
- PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial (2022) (67)
- Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (2018) (67)
- Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis (2016) (66)
- Stimulation of T cells through the CD3/T-cell receptor complex: role of cytoplasmic calcium, protein kinase C translocation, and phosphorylation of pp60c-src in the activation pathway (1987) (65)
- Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. (2010) (65)
- Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (2016) (64)
- Glycan-directed CAR-T cells (2018) (64)
- Immunotherapy for Glioblastoma: Adoptive T-cell Strategies (2018) (64)
- Addition of Deoxynucleosides Enhances Human Immunodeficiency Virus Type 1 Integration and 2LTR Formation in Resting CD4+ T Cells (2007) (64)
- Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferation (2002) (63)
- Immunotherapy opportunities in ovarian cancer (2008) (62)
- Immunotherapy for Brain Tumors. (2017) (62)
- Correlation of hypomagnesemia with the onset of cyclosporine-associated hypertension in marrow transplant patients. (1986) (62)
- Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes (2011) (61)
- Immunopathological aspects of Plasmodium berghei infection in five strains of mice. II. Immunopathology of cerebral and other tissue lesions during the infection. (1980) (61)
- T-cell therapy at the threshold (2012) (61)
- Novel cell and gene therapies for HIV. (2012) (60)
- Costimulatory approaches to adoptive immunotherapy. (1998) (60)
- Nature of Tumor Control by Permanently and Transiently Modified GD2 Chimeric Antigen Receptor T Cells in Xenograft Models of Neuroblastoma (2014) (60)
- Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells (2017) (60)
- Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. (2020) (59)
- Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM) (2017) (59)
- Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You (2016) (58)
- Novel Role of Phosphatidylinositol 3-Kinase in CD28-mediated Costimulation* (2001) (58)
- CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. (2019) (58)
- The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function (2021) (56)
- Opposing effects of CTLA4-Ig and Anti-CD80 (B7-1) plus Anti-CD86 (B7-2) on experimental allergic encephalomyelitis (1996) (56)
- T-cell activation is required for efficient replication of human herpesvirus 6 (1990) (56)
- Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer (2017) (56)
- Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. (2011) (55)
- Stimulation of CD5 enhances signal transduction by the T cell antigen receptor. (1990) (55)
- Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. (2006) (54)
- The protein tyrosine kinase inhibitor herbimycin A, but not genistein, specifically inhibits signal transduction by the T cell antigen receptor. (1992) (53)
- Prolonged survival and tissue trafficking following adoptive transfer of CD 4 z gene-modified autologous CD 4 1 and CD 8 1 T cells in human immunodeficiency virus – infected subjects (53)
- Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy (2022) (52)
- Mitogen-induced genes are subject to multiple pathways of regulation in the initial stages of T-cell activation (1989) (52)
- Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules. (1995) (52)
- Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence (2017) (52)
- Costimulation Light: Activation of CD4+ T Cells with CD80 or CD86 Rather Than Anti-CD28 Leads to a Th2 Cytokine Profile1 (2000) (51)
- Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. (1996) (51)
- Distinct Effects of IL-18 on the Engraftment and Function of Human Effector CD8+ T Cells and Regulatory T Cells (2008) (51)
- Mitogenic stimulation of T cells reveals differing contributions for B7‐1 (CD80) and B7‐2 (CD86) costimulation (1997) (51)
- Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells. (2017) (51)
- Changing the Mindset in Life Sciences Toward Translation: A Consensus (2014) (50)
- Regulation of interleukin 3 gene induction in normal human T cells. (1989) (50)
- Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? (2012) (50)
- Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. (1998) (48)
- Engineering T cells for cancer: our synthetic future (2014) (48)
- miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. (2016) (48)
- Primary porcine endothelial cells express membrane-bound B7-2 (CD86) and a soluble factor that co-stimulate cyclosporin A-resistant and CD28-dependent human T cell proliferation. (1996) (47)
- The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy (2015) (47)
- T-cell immunotherapy: looking forward. (2014) (47)
- Adoptive immunotherapy: good habits instilled at youth have long-term benefits (2008) (46)
- Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells (2021) (45)
- Circulating and tissue-bound immune complex formation in murine malaria. (1979) (45)
- T-cell reconstitution and expansion after hematopoietic stem cell transplantation: ‘T’ it up! (2005) (45)
- Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. (2018) (44)
- Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. (2015) (44)
- Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells (2014) (44)
- Perspective: Assembly line immunotherapy (2013) (44)
- Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). (2016) (43)
- NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus (2010) (43)
- Potential roles of the B7 and CD28 receptor families in autoimmunity and immune evasion. (1995) (43)
- National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (2011) (43)
- Extensive Replicative Capacity of Human Central Memory T Cells1 (2004) (43)
- Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (2021) (42)
- Measurement of Intracellular Calcium Ions by Flow Cytometry (1997) (42)
- Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. (2011) (42)
- Mesothelin expression is associated with poor outcomes in breast cancer (2014) (41)
- Dual CD 19 and CD 123 targeting prevents antigen-loss relapses after CD 19-directed immunotherapies (2019) (41)
- Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kDa B-cell growth factor and anti-CD19. (1988) (40)
- Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice (2016) (40)
- Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells (2004) (40)
- The road to recovery: translating PD-1 biology into clinical benefit. (2007) (40)
- Complex effects of phenylarsine oxide in T cells. Induction of tyrosine phosphorylation and calcium mobilization independent of CD45 expression. (1993) (40)
- Primary human CD4+ T cells contain heterogeneous I kappa B kinase complexes: role in activation of the IL-2 promoter. (1999) (39)
- Rapid activation of C-Raf-1 after stimulation of the T-cell receptor or the muscarinic receptor type 1 in resting T cells. (1993) (39)
- Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL (2015) (39)
- Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. (2017) (39)
- Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18 (2009) (39)
- Signal transduction in T cells. (1991) (39)
- A Novel System for Simultaneous in Vivo Tracking and Biological Assessment of Leukemia Cells and ex Vivo Generated Leukemia-Reactive Cytotoxic T Cells (2004) (38)
- Adoptive Transfer of Autologous T Cells Improves T-cell Repertoire Diversity and Long-term B-cell Function in Pediatric Patients with Neuroblastoma (2012) (38)
- Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond. (2013) (38)
- Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus (2016) (38)
- Role of CD2 cross‐linking in cytoplasmic calcium responses and T cell activation (1988) (37)
- Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy (2011) (37)
- A rational mouse model to detect on-target off-tumor CAR T cell toxicity. (2020) (37)
- The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion. (1997) (37)
- Tumor Expression of 4-1BB Ligand Sustains Tumor Lytic T Cells (2003) (36)
- Regulation of 4F2 heavy-chain gene expression during normal human T-cell activation can be mediated by multiple distinct molecular mechanisms (1988) (36)
- Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD (2010) (36)
- Tyrosine kinase-regulated and inositol phosphate-independent Ca2+ elevation and mobilization in T cells. (1992) (36)
- A translational bridge to cancer immunotherapy (2003) (36)
- Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. (2015) (36)
- T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma (2016) (36)
- Persistent calcium elevation correlates with the induction of surface immunoglobulin-mediated B cell DNA synthesis (1993) (36)
- Flow cytometric measurement of intracellular ionized calcium in single cells with indo-1 and fluo-3. (1990) (35)
- The CD 28 Family : a T Cell Rheostat for Therapeutic Control of T Cell Activation (2004) (35)
- A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. (2019) (35)
- Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma. (2016) (35)
- Enhanced transmembrane signalling activity of monoclonal antibody heteroconjugates suggests molecular interactions between receptors on the T cell surface. (1989) (35)
- Surface immunoglobulin-mediated B-cell activation in the absence of detectable elevations in intracellular ionized calcium: a model for T-cell-independent B-cell activation. (1989) (35)
- CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL. (2017) (34)
- Anti-CD3/anti-CD28 bead stimulation overcomes CD3 unresponsiveness in patients with head and neck squamous cell carcinoma. (2000) (34)
- Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL (2013) (34)
- Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL. (2016) (33)
- Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. (2006) (33)
- Disseminated Fusarium moniliforme infection after allogeneic marrow transplantation. (1986) (33)
- iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity (2019) (33)
- Immunotherapy for Breast Cancer: Current and Future Strategies (2017) (33)
- Engineered cellular immunotherapies in cancer and beyond (2022) (33)
- Two distinct mechanisms of interleukin-2 gene expression in human T lymphocytes. (1989) (33)
- Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas. (2018) (33)
- Biochemical analysis of the immune B cell defect in xid mice. (1991) (32)
- Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. (2005) (32)
- Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model (2016) (32)
- T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL (2013) (32)
- Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells. (2002) (31)
- Zoom Zoom: Racing CARs for Multiple Myeloma (2013) (31)
- Measurement of CD69 induction in the assessment of immune function in asymptomatic HIV-infected individuals. (1997) (30)
- Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma (2016) (30)
- Considerations for the clinical application of chimeric antigen receptor T cells: Observations from a Recombinant DNA Advisory Committee symposium held June 15, 2010 (Cancer Research (2011) 71, (3175-3181)) (2011) (30)
- UV irradiation of lymphocytes triggers an increase in intracellular Ca2+ and prevents lectin-stimulated Ca2+ mobilization: evidence for UV- and nifedipine-sensitive Ca2+ channels. (1991) (30)
- Chapter 10 Intracellular Ionized Calcium (1994) (30)
- Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. (2013) (30)
- Glucocorticoids suppress calcium mobilization and phospholipid hydrolysis in anti-Ig antibody-stimulated B cells. (1987) (30)
- Very-Low-Dose Streptozotocin Induces Diabetes in Insulin Promoter-mB7-1 Transgenic Mice (1995) (30)
- The CD28 and CTLA-4 receptor family. (1994) (30)
- Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation. (2007) (30)
- Measurement of Intracellular Ions by Flow Cytometry (1995) (29)
- CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication. (2021) (29)
- CD28 and staphylococcal enterotoxins synergize to induce MHC-independent T-cell proliferation. (1992) (29)
- A Cure for HIV Infection: “Not in My Lifetime” or “Just Around the Corner”? (2016) (29)
- Transcription of T cell antigen receptor genes is induced by protein kinase C activation. (1988) (28)
- Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells. (1999) (28)
- Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide (2016) (28)
- Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. (2019) (27)
- B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis (1995) (27)
- Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design (2020) (27)
- SAP: natural inhibitor or grand SLAM of T cell activation? (2001) (27)
- CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. (2021) (27)
- Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL (2012) (26)
- Interferon β adenoviral gene therapy in a patient with ovarian cancer (2006) (26)
- Ligand-stimulated signaling events in immature CD4+CD8+ thymocytes expressing competent T-cell receptor complexes. (1991) (25)
- Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer. (2016) (25)
- Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety. (2016) (25)
- Intracellular ionized calcium. (1994) (25)
- Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL (2015) (25)
- Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL. (2016) (25)
- BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. (2021) (25)
- Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. (2013) (25)
- Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19 (2013) (24)
- Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia (2015) (24)
- In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines (2017) (24)
- The role of co-stimulation in regulation of chemokine receptor expression and HIV-1 infection in primary T lymphocytes. (1998) (24)
- Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections (2016) (24)
- T cell engineering as therapy for cancer and HIV: our synthetic future (2015) (24)
- Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19 (2020) (23)
- Bimodal effect of phorbol ester on B cell activation. Implication for the role of protein kinase C. (1991) (23)
- Lack of Coreceptor Allows Survival of Chronically Stimulated Double-Negative α/β T Cells (2001) (23)
- Suppressor Function of Umbilical Cord Blood-Derived CD4+CD25+ T-Regulatory Cells Exposed to Graft-versus-Host Disease Drugs (2006) (23)
- T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL (2014) (23)
- Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers (2015) (23)
- Ruxolitinib Prevents Cytokine Release Syndrome after Car T-Cell Therapy Without Impairing the Anti-Tumor Effect in a Xenograft Model (2017) (23)
- Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment. (2017) (23)
- 4-1BB costimulation promotes human T cell adhesion to fibronectin. (1999) (23)
- Immunopathological aspects of Plasmodium berghei infection in five strains of mice. I. Immune complexes and other serological features during the infection. (1980) (22)
- Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma (2018) (22)
- Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy? (2017) (22)
- Anti-CD3/anti-CD28 monoclonal antibody-coated suture enhances the immune response of patients with head and neck squamous cell carcinoma. (1999) (22)
- Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. (2010) (22)
- Anti-Ig-mediated proliferation of human B cells in the absence of protein kinase C. (1988) (22)
- Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (2017) (22)
- Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL (2022) (21)
- Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. (2012) (21)
- Intracellular Survival Pathways against Glutamate Receptor Agonist Excitotoxicity in Cultured Neurons: Intracellular Calcium Responsesa (1999) (21)
- Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells. (2021) (21)
- Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas (2014) (20)
- Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy (2017) (20)
- Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy (2016) (20)
- Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation. (2013) (20)
- Drugging the Undruggable Ras - Immunotherapy to the Rescue? (2016) (20)
- A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells. (2019) (20)
- Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. (2020) (20)
- Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic‐Pharmacodynamic Modeling Approaches (2020) (20)
- Disease-Modifying Therapeutic Concepts for HIV in the Era of Highly Active Antiretroviral Therapy (2011) (19)
- CD28 co-receptor signal transduction in T-cell activation. (1997) (19)
- Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. (2020) (19)
- Trispecific antibodies offer a third way forward for anticancer immunotherapy (2019) (19)
- Examination of the inhibitory and stimulatory effects of IFN-α, -β, and -γ on human B-cell proliferation induced by various B-cell mitogens (1988) (19)
- Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells (2021) (19)
- Different patterns of inositol polyphosphate production are seen in B lymphocytes after cross-linking of sIg by anti-Ig antibody or by a multivalent anti-Ig antibody dextran conjugate. (1989) (18)
- Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues (2022) (18)
- Tumor-associated macrophages as a source of functional dendritic cells in ovarian cancer patients. (2002) (18)
- Flow cytometric measurement of cellular ionized calcium concentration. (1988) (18)
- Chimeric Antigen Receptor T Cells in Myeloma. (2016) (18)
- Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers. (2022) (18)
- Activation of human B lymphocytes by nanogram concentrations of anti‐IgM‐dextran conjugates (1990) (18)
- CARTs on the Road for Myeloma (2014) (18)
- 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes. (2010) (18)
- Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (2022) (17)
- Defective signal transduction by the CD2 molecule in immature T-cell receptor/CD3- thymocytes. (1992) (17)
- CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc). (2012) (17)
- Phase I clinical trial of donor T-helper type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant. (2002) (17)
- Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma (2018) (17)
- CAR T cell viability release testing and clinical outcomes: is there a lower limit? (2019) (16)
- Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR (2016) (16)
- Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia (2021) (16)
- Development of an animal model for autotransfusion therapy: in vitro characterization and analysis of anti-CD3/CD28 expanded cells. (1998) (16)
- Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia (2016) (16)
- Variations in thymocyte susceptibility to clonal deletion during ontogeny. Implications for neonatal tolerance. (1991) (16)
- Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL). (2017) (16)
- CD45 tyrosine phosphatase activity and membrane anchoring are required for T-cell antigen receptor signaling. (1994) (16)
- Calcium-independent calcineurin regulation (2003) (15)
- Adoptive cellular therapy. (2011) (15)
- Cross-linkage of Ly-6A/E induces Ca2+ translocation in the absence of phosphatidylinositol turnover and mediates proliferation of normal murine B lymphocytes. (1991) (15)
- Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy. (2016) (15)
- FoxP3 Mediated Induction of Pim 2 Allows T Regulatory Cells to Preferentially Expand in Rapamycin (2008) (15)
- PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells (2018) (15)
- The CD28 and CTLA-4 Receptor Family (Part 1 of 2) (1994) (15)
- Potentiating adoptive cell therapy using synthetic IL-9 receptors (2022) (14)
- Analysis of antigen receptor signaling in B cells from mice with a retrovirus-induced acquired immunodeficiency syndrome. (1995) (14)
- Next-Generation CAR T-cell Therapies. (2022) (14)
- T-Cell Immunotherapy: Looking Forward: T Cell Immunotherapy: Optimizing Trial Design Bethesda, Maryland 10-11 September 2013. (2014) (14)
- T-cell-targeted immunotherapy. (1992) (14)
- Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma (2021) (14)
- Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. (2015) (14)
- Detection of antigen specific T lymphocytes by determination of intracellular calcium concentration using flow cytometry. (1992) (14)
- Phase I Trial of Adoptive Cell Transfer with Mixed-Profile Type-I/Type-II Allogeneic T Cells for Metastatic Breast Cancer (2011) (14)
- Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer-Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT (2012) (14)
- Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation (2017) (13)
- Shortened T cell culture with IL-7 and IL-15 provides the most potent chimeric antigen receptor (CAR)-modified T cells for adoptive immunotherapy. (2016) (13)
- The promise of T-lymphocyte immunotherapy for the treatment of malignant disease. (2001) (13)
- Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. (2019) (13)
- Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms (2016) (13)
- Multiplex Cripsr/Cas9 Genome Editing to Generate Potent Universal CART and PD1-Deficient Cells Against Leukemia (2015) (13)
- Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans. (2018) (13)
- Anti-CD 19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma (2018) (13)
- Adoptive Therapy with T Cells/NK Cells (2007) (12)
- Interferon beta adenoviral gene therapy in a patient with ovarian cancer. (2006) (12)
- Lack of coreceptor allows survival of chronically stimulated double-negative alpha/beta T cells: implications for autoimmunity. (2001) (12)
- A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD 3 / CD 28 costimulation (2006) (12)
- CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL). (2020) (12)
- Efficient Termination of CD123-Redirected Chimeric Antigen Receptor T Cells for Acute Myeloid Leukemia to Mitigate Toxicity (2015) (12)
- Abstract 4575: Chimeric antigen receptor macrophages (CARMA) for adoptive cellular immunotherapy of solid tumors (2017) (12)
- Protein kinase C activation in B cells by indolactam inhibits anti-Ig-mediated phosphatidylinositol bisphosphate hydrolysis but not B cell proliferation. (1990) (12)
- Novel Chimeric Antigen Receptor T Cells for the Treatment of Hodgkin Lymphoma (2014) (12)
- CD19‐DIRECTED CAR T CELL THERAPY (CTL019) FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL AND FOLLICULAR LYMPHOMAS: FOUR YEAR OUTCOMES (2019) (12)
- Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models (2013) (12)
- Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma (2019) (12)
- Absorbable microparticulate cation exchanger for immunotherapeutic delivery. (2004) (12)
- TRANCE-and CD 40 Ligand-matured Dendritic Cells Reveal MHC Class I-restricted T Cells Specific for Autologous Tumor in Late-Stage Ovarian Cancer Patients 1 (2003) (12)
- CARs on Track in the Clinic: Workshop of the Blood and Marrow Transplant Clinical Trials Network Subcommittee on Cell and Gene Therapy Washington DC, 18 May 2010. (2011) (11)
- Adoptive Transfer of Umbilical Cord Blood (UCB)-Derived Regulatory T Cells (Tregs) to Recipients of Nonmyeloablative Unrelated Double UCB Transplantation. (2009) (11)
- Phase I trial of autologous cMET-directed CAR-t cells administered intravenously in patients with melanoma & breast carcinoma. (2020) (11)
- Measurement of Intracellular Ions by Flow Cytometry (2004) (11)
- Improved detection of immune complexes in human and mouse serum using a microassay adaptation of the C1Q binding test. (1979) (11)
- Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CAR T Cell Efficacy (2018) (11)
- Targeting CLEC12A with Chimeric Antigen Receptor T Cells Can Overcome the Chemotherapy Refractoriness of Leukemia Stem Cells (2017) (11)
- Predicting cytokine storms: it's about density. (2011) (11)
- Adoptive immunotherapy: new ways to skin the cat? (2005) (11)
- Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. (2016) (11)
- Boosting engineered T cells (2019) (10)
- Monoclonal TCR-redirected tumor cell killing. Nat Med (2012) (10)
- Emerging Use of CRISPR Technology - Chasing the Elusive HIV Cure. (2019) (10)
- Blocking HIV's attack. (2012) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study (2020) (10)
- IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA (2015) (10)
- Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of epigenome. (2020) (10)
- Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells (2016) (10)
- Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies (2015) (10)
- Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer (2021) (10)
- Differential sensitivity of human leukocyte subpopulations to ultraviolet light. (1989) (10)
- Impaired Induction of the Apoptosis-Protective Protein Bcl-xL in Activated PBMC from Asymptomatic HIV-Infected Individuals (1997) (10)
- Introduction to Functional Cell Assays (1993) (10)
- Correction: CD28-deficient mice generate and impaired th2 response to Schistosoma mansoni infection (European Journal of Immunology (1996) 26 (10) (2448-2455)) (1997) (9)
- Humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 induce remissions in children and young adults with relapsed/refractory lymphoblastic leukemia/lymphoma (2017) (9)
- CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells (2020) (9)
- Post-transplant adoptive T-cell immunotherapy. (2008) (9)
- CD 28 IS AN INDUCIBLE T CELL SURFACE ANTIGEN THAT TRANSDUCES A : PROLIFERATIVE SIGNAL IN CD 3 MATURE THYMOCYTES ' (9)
- Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019). (2016) (9)
- The cytological features of CAR(T) cells (2016) (9)
- Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM) (2018) (9)
- High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses (2015) (9)
- First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. (2019) (9)
- Multiple cancer-specific antigens are targeted by a chimeric antibody receptor on a single cancer cell. (2019) (9)
- Measurements of Cell Physiology: Ionized Calcium, pH and Glutathione (1993) (9)
- Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia. (2017) (8)
- Toward synthetic biology with engineered T cells: a long journey just begun. (2014) (8)
- Cellular and growth-factor requirements for the replication of human herpesvirus 6 in primary lymphocyte cultures. (1990) (8)
- Distinct Signaling By Chimeric Antigen Receptors (CARs) Containing CD28 Signaling Domain Versus 4-1BB In Primary Human T Cells (2013) (8)
- Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy (2019) (8)
- Engineered T Cell Therapies from a Drug Development Viewpoint (2019) (8)
- Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications (2019) (8)
- Remote Controlled CARs: Towards a Safer Therapy for Leukemia (2016) (8)
- Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells (2021) (8)
- Programming the next generation of dendritic cells. (2007) (7)
- Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL (2014) (7)
- Signal transduction by B and T cells early after bone marrow transplantation: B cell calcium flux responses are intact whereas lack of CD4 cells accounts for impaired T cell responses. (1995) (7)
- CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia (2018) (7)
- Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies (2014) (7)
- Intact antigen receptor-mediated calcium signals in patients with early stage HIV-1 infection. (1996) (7)
- Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. (2022) (7)
- Ex vivo replicative potential of adult human peripheral blood CD4+ T cells. (1997) (7)
- B lymphocyte immunoglobulin receptor desensitization is downstream of tyrosine kinase activation. (1994) (7)
- Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL) (2015) (6)
- CAR T cells targeting CD13 controllably induce eradication of acute myeloid leukemia with a single domain antibody switch (2021) (6)
- CTL019 Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor (CAR) T Cells to Characterize the Impact of Tocilizumab on Expansion and to Identify Correlates of Cytokine Release Syndrome Severity (2017) (6)
- Monitoring Therapeutic Response to Anti-Fibroblast Activation Protein (FAP) CAR T Cells using [18F]AlF-FAPI-74. (2022) (6)
- Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma (2019) (6)
- Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function (2021) (6)
- CD4 T cells to kiss off chemotherapy-resistant CMV? (2002) (6)
- Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism (2016) (6)
- Use of cell-based therapies for modification of host immune responses. (2003) (6)
- Examination of the inhibitory and stimulatory effects of IFN-alpha, -beta, and -gamma on human B-cell proliferation induced by various B-cell mitogens. (1988) (6)
- Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy. (2021) (6)
- CTL019 Clinical Pharmacology and Biopharmaceutics in Pediatric Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (2017) (6)
- Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells (2016) (6)
- Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation (2015) (5)
- Signal transduction properties of the T cell activation monoclonal antibody panel: ubiquitous increase in cellular substrate tyrosine phosphorylation in the absence of detectable calcium mobilization. (1996) (5)
- Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cells (2021) (5)
- Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells (2012) (5)
- Cytokine Release Syndrome in Severe COVID 19: Lessons From Arthritis and Cell Therapy in Cancer Patients Point to Therapy for Severe Disease (2020) (5)
- Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells (2015) (5)
- A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL). (2013) (5)
- Title: Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells Short Title: Constitutive CAR T-cell proliferation (2015) (5)
- CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production (2021) (5)
- Effect of chimeric antigen receptor (CAR) T cells on clonal expansion of endogenous non-CAR T cells in patients (pts) with advanced solid cancer. (2017) (5)
- Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia (2021) (5)
- 180 - Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL) (2017) (5)
- 758. Towards Gene Knock out Therapy for AIDS/HIV: Targeted Disruption of CCR5 Using Engineered Zinc Finger Protein Nucleases (ZFNs) (2006) (5)
- Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment (2016) (5)
- Alcoholic ketoacidosis and isopropyl alcohol intoxication. (1978) (5)
- Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2021) (5)
- Measurement of Intracellular Ions by Flow Cytometry (1995) (5)
- Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy (2015) (5)
- T-Rapa Cell Clinical Products Contain a Balance of Minimally Differentiated Th2/Th1 Effector Cells Depleted of Treg Cells (2010) (5)
- 974. Towards Gene Knock out Therapy for AIDS/HIV: Targeted Disruption of CCR5 Using Engineered Zinc Finger Protein Nucleases (ZFNs) (2005) (5)
- iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity (2019) (4)
- CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL (2021) (4)
- Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones (2018) (4)
- TCancer Patients Directly Inhibit Autologous Cutting Edge : Regulatory T Cells from Lung (2002) (4)
- 638. TGFBeta Signaling Blockade within PSMA Targeted CAR Human T Cells for the Eradication of Metastatic Prostate Cancer (2016) (4)
- Abstract PR06: T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL (2014) (4)
- Analysis of lymphocyte activation and metabolism by flow cytometry. (1992) (4)
- Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) (2016) (4)
- Program death-1 (PD-1) signaling and regulatory T cells (Tregs) collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes (CTLs) in advanced acute myeloid leukemia (AML) Running title: PD-1 blockade and adoptive CTL therapy for AML (2010) (4)
- Voices of biotech (2016) (4)
- Cytokine Storm. Reply. (2021) (4)
- Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia (2016) (4)
- Microenvironment and Immunology Enhanced Effector Responses in Activated CD 8 þ T Cells De fi cient in Diacylglycerol Kinases (2013) (4)
- Distinct Roles for B 7-1 ( CD-80 ) and B 7-2 ( CD-86 ) in the Initiation of Experimental Allergic Encephalomyelitis (2013) (4)
- The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. (2021) (4)
- Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models (2017) (4)
- Production of Human CRISPR-Engineered CAR-T Cells. (2021) (4)
- Responsiveness of fetal and adult CD4-, CD8- thymocytes to T cell activation. (1989) (4)
- A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients. (2021) (4)
- 211. CD2, the First Identified T cell Co-Stimulator, Demonstrates More Effective Chimeric Antigen Receptor Activity Over CD28 and 4-1BB (2015) (3)
- Adoptive immunotherapy with autologous CD3/CD28-costimulated T cells after fludarabine-based chemotherapy in patients with chronic lymphocytic leukemia. (2011) (3)
- Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells (2020) (3)
- Monosomy 1p36 uncovers a role for OX40 in survival of activated CD4+ T cells. (2008) (3)
- A phase I trial of cyclosporine for hospitalized patients with COVID-19 (2022) (3)
- Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment After Low-Intensity Chemotherapy (2010) (3)
- Cancer Killers. (2017) (3)
- Impact of Humoral Immunogenicity (Anti-mCAR19 Antibodies) on CTL019 Cellular Kinetics, Efficacy, and Safety (2017) (3)
- Abstract 3525: IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma (2012) (3)
- 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015). (2015) (3)
- Adoptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells (ACTC) Enhances Numeric and Functional Lymphocyte Recovery after Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma. (2005) (3)
- Adoptive transfer of ex vivo costimulated autologous T-cells after autotransplantation for myeloma (MM)accelerates post-transplant T-cell recovery (2004) (3)
- Stimulation of CD 5 Enhances Signal Transduction by the T Cell Antigen Receptor (3)
- Adoptive Transfer of Ex Vivo Costimulated Autologous T-Cells in Conjunction with Pneumococcal Conjugate Vaccine Immunizations Accelerates Post-Transplant T-Cell Recovery after Autotransplantation for Myeloma: Results of a Randomized Study. (2004) (3)
- The 4F2 heavy chain gene: a molecular model of inducible gene expression in human T cells. (1989) (3)
- T Cell Immunotherapy: Optimizing Trial Design (2014) (3)
- Expression of the human epidermal growth factor receptor in a murine T-cell hybridoma. A transmembrane protein tyrosine kinase can synergize with the T-cell antigen receptor. (1992) (3)
- Abstract PR07: Human chimeric antigen receptor (CAR) macrophages for cancer immunotherapy (2020) (3)
- CAR T Cells Secreting IL18 Augment Antitumor Immunity and Increase T Cell Proliferation and Costimulation (2017) (3)
- Serial Killers and Mass Murderers: Engineered T Cells Are up to the Task (2015) (3)
- Signal Transduction in T Cell Activation and Tolerance (1993) (3)
- CD33 Directed Chimeric Antigen Receptor T Cell Therapy As a Novel Preparative Regimen Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia (2015) (3)
- Isolation of a new herpes-virus from human CD4+ T cells (1990) (3)
- Potential Clinical Applications of Signal Transduction Measurements in Marrow Transplantation and HIV‐1 Infection a (1993) (3)
- Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation. (2004) (3)
- with umbilical cord blood: safety profile and detection kinetics Infusion of ex vivo expanded T regulatory cells in adults transplanted (2011) (3)
- Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia (2017) (3)
- Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy. (2023) (3)
- Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy (2022) (2)
- Abstract LB-083: Phase I study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma (2016) (2)
- Improved Anti-Leukemia Activities of Adoptively Transferred T Cells Expressing Bites (2015) (2)
- Effective targeting of primary human acute myeloid leukemia using anti-CD123 chimeric antigen receptor engineered T cells (2013) (2)
- Adoptive Immune Responses to Sars-Cov2 Vaccination in CART19 Treated Patients (2021) (2)
- Enhancing T cell persistence of CAR-redirected T cells in solid tumors (2014) (2)
- Adaptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells Enhances Lymphocyte Recovery after Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma. (2006) (2)
- Abstract 60: Induction of T cell dysfunction and NK-like T cell differentiation in vitro and in patients after CAR T cell treatment (2021) (2)
- Response from Carroll et al. (1997) (2)
- Single-cell antigen-specific activation landscape of CAR T infusion product identifies determinants of CD19 positive relapse in patients with ALL (2021) (2)
- Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control (2016) (2)
- Utility of FDG-PET/CT in lymphoma patients undergoing immunotherapy with autologous CTL019 T-cells. (2015) (2)
- Sustained Functional T Cell Persistence and B Cell Aplasia Following CD19-Targeting Adoptive T Cell Immunotherapy for Relapsed, Refractory CD19+ Malignacy (2012) (2)
- Pre-clinical validation of a humanized anti-EGFR variant III chimeric antigen receptor and phase I trial of CART-EGFRvIII in glioblastoma (2014) (2)
- Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. (2022) (2)
- Miniatures Mesothelin-Speci fi c Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies (2014) (2)
- CAR T-cell Therapy Meets Clonal Hematopoiesis. (2022) (2)
- Abstract LB-156: Improved T cell survival, tumor localization and tumor eradication by folate receptor-alpha redirected T cells is achieved by provision of CD137 costimulatory signaling (2011) (2)
- 69. Adoptive T-cell Therapy for Malignancy in the Setting of Hematopoietic Cell Transplantation (2016) (2)
- IL-21 promotes the expansion of CD27+CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells (2013) (2)
- 76 – Principles of tumor immunology (2013) (2)
- First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies (2008) (2)
- Adoptive transfer of gene-modified T-cells engineered to express high-affinity tcr's for cancer-testis antigens NY-ESO-1 or lage-1, in multiple myeloma (MM) patients post autologous hematopoietic stem cell transplant (ASCT) (2013) (2)
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia (2018) (2)
- 1003. HIV-1-Derived Lentivirus Vector-Based Antisense Gene Therapy: Towards an Alternative Treatment for HIV/AIDS (2004) (2)
- Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells (2023) (2)
- Pilot study of redirected autologous T cells engineered to contain anti-CD19 attached to TCRζ and 4-1BB signaling domains in patients with chemotherapy-resistant or -refractory CD19+ leukemia and lymphoma. (2013) (2)
- Author Correction: Targeting cardiac fibrosis with engineered T cells (2019) (2)
- The CD 45 Tyrosine Phosphamse Regulates Phosphotyrosine Homeostasis and Its Loss ReveMs a Novel Pattern of Late T Cell Receptor-induced Ca 2 + Oscillations (2003) (2)
- tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells (2013) (2)
- Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Syndrome in B-Cell ALL Patients Receiving CART19. (2022) (2)
- Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. (2022) (2)
- Abstract 3749: Genetic blockade of the protein tyrosine phosphatase SHP1 augments CAR T cell activity against PDL1 expressing solid tumors (2017) (2)
- Can't Get Any Help? New Approaches for Adoptive Immunotherapy of Cancer. (2001) (2)
- Bioluminescent Tracking of Human and Mouse Acute Lymphoblastic Leukemia Reveals Potent Immunogenicity of Luciferase In Some Preclinical Models of Leukemia (2010) (2)
- Phase I study of autologous T cells bearing fully-humanized chimeric antigen receptors targeting mesothelin in mesothelin- expressing cancers (314) (2022) (2)
- Productive Infection of Neonatal CD 8 1 T Lymphocytes by HIV-1 By (1998) (2)
- Impaired tumor death receptor signaling drives resistance to CAR T cell therapy (2019) (2)
- This information is current as Autoimmune Encephalomyelitis Onset Ameliorates Experimental of Encephalitogenic T Cells or After Disease Blockade of CD 28 During In Vitro Activation (1999) (2)
- A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia (2019) (2)
- Oncolytic Adenovirus Expressing Cytokines Enhances Anti-Tumor Efficacy of Mesothelin-Redirected CAR-T Cells (2016) (2)
- T-Rapa Cell DLI Safely Balances Th1/Th2 Cytokine Activation After Low-Intensity Allogeneic Hematopoietic Cell Transplantation (2011) (2)
- L-selectin expression defines a subpopulation of In vitro generated AML-reactive T-cells with superior anti-leukemic efficacy for adoptive immunotherapy (2004) (2)
- 515. Oncolytic Adenovirus Armed with Cytokines Enhances CAR-T Cell Efficacy in Pancreatic Tumor Model (2016) (2)
- Comparative trial of imipenem and moxalactam in the treatment of serious bacterial infections (1986) (2)
- On the nature of early mortality in murine malaria. (1980) (2)
- Ultrasonography and Computed Tomography in Severe Urinary Tract Infection (1985) (2)
- Scholler Antigen Receptor T Cells Decade-Long Safety and Function of Retroviral-Modified Chimeric (2012) (1)
- Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. (2020) (1)
- Series ANTIBODY DERIVATIVES AS NEW THERAPEUTICS FOR HEMATOLOGIC MALIGNANCIES Antibody-modi fi ed T cells : CARs take the front seat for hematologic malignancies (2014) (1)
- malignancies Antibody-modified T cells: CARs take the front seat for hematologic (2014) (1)
- Epitope Editing in Hematopoietic Cells Enables CD45-Directed Immune Therapy (2022) (1)
- Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19 (2021) (1)
- myeloablation using chimeric antigen receptor Preclinical targeting of human acute myeloid leukemia (2014) (1)
- Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT (2013) (1)
- In Vitro Induction of Human Regulatory T-Cells (iTregs) Using Conditions of Low Tryptophan Plus Kynurenines (2016) (1)
- The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies (2021) (1)
- Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells) (2020) (1)
- Development of novel substrates for tumor immunotherapy. (2003) (1)
- Autologous aGVHD Associated with Infusion of T-Cells with Engineered Specificity for NY-ESO-1 and LAGE-1 Following High-Dose Melphalan and ASCT in Patients with Multiple Myeloma (2013) (1)
- Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects (2021) (1)
- T-Rapa6 and T-Rapa12 Cells Differentially Mediate Acute Gvhd after Low-Intensity Allogeneic HCT (2014) (1)
- Calcium Mobilization and Enhanced Natural Killer Function in Large Granular Lymphocytes Result from Cross-Linking the CD2 E-Rosette and CD16 Fc-Receptor (1987) (1)
- Targeting cardiac fibrosis with engineered T cells (2019) (1)
- transposon system Sleeping Beauty Stable gene transfer and expression in human primary T cells by the (2012) (1)
- Abstract 2900: IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma (2014) (1)
- AACR Calls on Congress to Take Immediate Action Against COVID-19 and Protect Patients with Cancer During the Pandemic. (2020) (1)
- Impact of CAR T-cell product viability on B-cell lymphoid malignancy outcomes (2019) (1)
- Studying Immunoreceptor Signaling in Human T Cells Using Electroporation of In Vitro Transcribed mRNA. (2017) (1)
- CAR T Cell Cytotoxicity Is Dependent on Death Receptor-Driven Apoptosis (2018) (1)
- Induction of a CD8 T cell intrinsic DNA damage and repair response is associated with clinical response to PD-1 blockade in uterine cancer (2022) (1)
- Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies, (2011) (1)
- Establishing Safety in the Clinic for the First Lentiviral Vector To Be Tested in Humans. (2004) (1)
- Abstract PL03-01: CAR T cells for leukemia and more (2012) (1)
- Abstract 4961: Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12 (2019) (1)
- 1075. Phase I Clinical Trial Demonstrates Safety and Feasibility of Autologous Cellular Therapy with Lentiviral Modified CD4 T Cells Expressing Anti-HIV Antisense in Patients with HAART Resistant HIV-1 Infection (2005) (1)
- Adoptive Cellular Therapy With Synthetic T Cells as an “Instant Vaccine” for Cancer and Immunity (2016) (1)
- Circulating immune complexes in malaria. (1980) (1)
- Gene expression signatures of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with CLL and ALL. (2017) (1)
- Publisher Correction: Potentiating adoptive cell therapy using synthetic IL-9 receptors (2022) (1)
- Are affinity-enhanced T cells the future of HIV therapy? (2009) (1)
- Rethinking the Regulatory Infrastructure for Human Gene Transfer Clinical Trials. (2016) (1)
- Anti-CD 3 / Anti-CD 28 Monoclonal Antibody – Coated Suture Enhances the Immune Response of Patients With Head and Neck Squamous Cell Carcinoma (1999) (1)
- B‐cell maturation antigen chimeric antigen receptor T‐cell re‐expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor‐based combination therapy (2021) (1)
- Rapid T Cell Recovery and Possible Auto-GVHD Following Adoptive Transfer of Ex-Vivo Costimulated Autologous T Cells at Day +2 Post-Transplant. (2007) (1)
- Prophylactic Administration Of Ex VIVO Co-Stimulated Donor Lymphocyte Infusion (DLI) From Related And Unrelated Donors After Reduced Intensity Conditioning For High Risk Hematologic Malignancies (2009) (1)
- Co-stimulated autologous T-cell infusion after autologous stem cell transplantation (SCT) for myeloma accelerates lymphocyte recovery and augments response to pneumoccal vaccine: Results of a randomized trial (2005) (1)
- Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses (2013) (1)
- Activation of human b lymphocytes by nanogram concentrations of anti igm coupled to dextran (1989) (1)
- Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming (2015) (1)
- Abstract 3187: Depleting cells expressing fibroblast activation protein disrupts tumor-promoting desmoplasia (2015) (1)
- Phase 1 Trial of Cyclosporine for Hospitalized Patients with COVID-19 (2021) (1)
- Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. (2022) (1)
- Chimeric Immunoreceptor (T-Body) Targeting of Acute B-Cell Lymphoblastic Leukemia (B-ALL) through Lentivirus Engineering of Primary Human T Cells. (2006) (1)
- 515. Targeting Hypoglycosylation with a Chimeric Antigen Receptor (2015) (1)
- Selective Reprogramming of Cd19-Specific T Cells With IL-21 and CD28 Signaling for Adoptive Immunotherapy of Acute Lymphoblastic Leukemia (2009) (1)
- Abstract B139: Toxicity testing of EGFRvIII CAR-based immunotherapy of glioblastoma: From bench to bedside (2016) (1)
- Methods for selectively stimulating the proliferation of T-cells (1994) (1)
- The role of CD4+CD25+ T regulatory (Treg) cells in allogeneic bone marrow transplantation (2004) (1)
- Chimeric antigen receptor modified T cells directed against CD19 (CTL019) induce clinical responses in patients with relapsed or refractory CD19+ lymphomas (2015) (1)
- Abstract A123: Skewed CD4 and CD8 T-cell differentiation in pancreatic cancer patients (2019) (1)
- Disruption of desmoplastic stroma overcomes restrictions to T cell extravasation, immune exclusion and immunosuppression in solid tumors (2023) (0)
- Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT (2012) (0)
- CellsHHuman T The Inducible Costimulator ( ICOS ) Is Critical for the Development of (2010) (0)
- A Novel Small Animal Model to Test on-Target Off-Tumor Cytoxicity of Adoptive Immune Therapies (2015) (0)
- Treatment of cancer using humanized chimeric anti-CD19 antigen receptor (2014) (0)
- Prevention of Acute GVHD by Ex Vivo Expanded Umbilical Cord Blood Derived Regulatory T Cells (Treg) (2015) (0)
- PD-L1 Immuno-Gene Therapy Under Cell Fate Control: Persistence of Cellular Delivery Vehicle and Transgene Expression. (2009) (0)
- Abstract 5571: Disruption of cell-intrinsic checkpoint regulator CTLA-4 in CD19 directed CAR T cells provides clinical efficacy in CLL patients (2022) (0)
- Abstract PL07-04: Engineered T cell transfer for cancer immunotherapy in the era of synthetic biology: Challenges and opportunities. (2013) (0)
- 719. Combination of ICOS and 4-1BB in a Third Generation CAR Exhibits Enhanced T Cell Persistence and Increased Antitumor Effect (2015) (0)
- Results of a Phase I/II Randomized Immunotherapy Trial Testing Adoptive Transfer of Co-Stimulated Autologous T Cells and Pneumococcal Conjugate Vaccine (PCV) Immunization after Autotransplantation for Myeloma (MM). (2004) (0)
- Abstract B05: A biologic screen to evaluate potential toxicity of chimeric antigen receptor modified T cells against primary normal human tissues (2015) (0)
- Antibody and B 7 / BBl-mediated Ligation of the CD 28 Receptor Induces Tyrosine Phosphorylation in Human T Cells (2003) (0)
- Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T cells Administered Intravenously in Patients with Melanoma & Breast Carcinoma (2023) (0)
- Intact function of TIL and PBL T cells from early stage NSCLC (2000) (0)
- Abstract 3972: Carpet bombing with CARs: Influence of dose, timing, lymphodepletion and costimulatory domain on efficacy of mRNA engineered anti-CD19 Chimeric Antigen Receptor T cells in preclinical xenograft models. (2013) (0)
- Peripheral NK Cell Activation and Expansion by Artificial Antigen Presenting Cells, 2D11 (41.25) (2009) (0)
- Mesothelin expression as a predictive biomarker of breast cancer outcomes. (2014) (0)
- Abstract 3602: Mechanisms of CAR T cell dysfunction and identification of transcription factors that drive the exhaustion phenotype (2022) (0)
- SP-024 CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS FOR RELAPSED,REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (2014) (0)
- Primary Human CD4 T Lymphocytes , and IL-2 Expression in L 3-Kinase, Bcl-x Distinct Regulation of Phosphatidylinositol Src Homology 2 Binding Domains Show CD28 and Inducible Costimulatory Protein (2003) (0)
- HIV conditionally replicating lentiviral vector expressing long antisense to Antiviral effects of autologous CD 4 T cells genetically modified with a (2013) (0)
- Abstract 5616: Soluble, high affinity TCRs fused to anti-CD3 redirect T cells to kill cancer cells presenting MAGE-A3 and NY-ESO antigens (2010) (0)
- Abstract IA01: Single cell analysis of CRISPR T cells (2020) (0)
- Abstract KN01: Updates on engineered T cells as cancer therapies (2015) (0)
- Abstract IA13: Engineered T cells for cancer therapy (2016) (0)
- Cell Differentiation from a Human Cell Line Pathways in CD34+ Progenitor to Dendritic Evidence for Distinct Intracellular Signaling (2013) (0)
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells (2018) (0)
- Supraphysiologic TCRs Generate Polyfunctional CD8 T Cells That Effectively Re‐directed the CD8 T cell Immune Response (2008) (0)
- Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy (2014) (0)
- expressed on artificial antigen-presenting cells of tumor necrosis factor receptor family members OX40 and 4-1BB Umbilical cord blood regulatory T-cell expansion and functional effects (2013) (0)
- 77 – Tumor immunotherapy (2013) (0)
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell (2018) (0)
- Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia (2021) (0)
- PRIMARY HIV ISOLATES THAT ARE DUAL-TROPIC FOR THE CHEMOKINE RECEPTORS ccR5 AND cxcR4 (FUSIN, LESTR): 53 (1997) (0)
- Continued observation and the collection of more data will be required to better define the relationship between skin lesions and CAR T-cell therapies (2016) (0)
- The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations (2018) (0)
- modified T cells - myeloablation using chimeric antigen receptor Preclinical targeting of human acute myeloid leukemia and (2014) (0)
- Immunotherapy Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma (2018) (0)
- Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma (2023) (0)
- The Unlikely Development of CAR T Cells: a Brief History and Prospects for the Future. (2023) (0)
- Differential signaling responses may promote proliferation and survival of chimeric antigen receptors linked to 4-1BB:CD3ζ. (P4356) (2013) (0)
- Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia (2011) (0)
- Anti-CD123 chimeric antigen receptor redirected T cells for relapsed B-cell acute lymphoblastic leukemia (2014) (0)
- Stimulation of the antigen receptor complex leads to transcriptional activation of the c-myc gene in normal human T cells. (1988) (0)
- The CD28 and CTLA-4 Receptor Family (Part 2 of 2) (1994) (0)
- T Regulatory Expansion and Function CD 28 Costimulation Is Essential for Human June and (2008) (0)
- Allogeneic Antitumor Vaccine Strategies (2003) (0)
- Abstract 4744: Soluble, high affinity TCRs fused to anti-CD3 redirect T cells to kill cancer cells presenting MAGE-A3 and NY-ESO antigens (2011) (0)
- Splenic B-Cells From Maids Mice Show a Selective Defect in Tyrosine Phosphorylation in Response to Igm Cross-Linking (1993) (0)
- Human T Cell Rapamycin Resistance And Th1/Tc1 Polarization Augment Xenogeneic Graft-Versus-Host Disease (2010) (0)
- Abstract IA16: Engineered T cell therapies for cancer. (2013) (0)
- Abstract LB-053: Next-generation sequencing of T-cell receptor-beta gene rearrangements reveals dramatic expansion of T-cell clonotypes after CART-EGFRvIII therapy for glioblastoma (2017) (0)
- Large-scale manufacture of car T cells engineered with augmented proliferative capacity and function via a 3-day process (2021) (0)
- Delivery technologies for cancer immunotherapy (2019) (0)
- Abstract 1787: ImmTACs: Bi-functional reagents for redirected tumour cell killing (2011) (0)
- Meeting Report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010 (2010) (0)
- Potentiating adoptive cell therapy using synthetic IL-9 receptors (2022) (0)
- 516. Chimeric Antigen Receptors With Distinct Signaling Domains Can Reprogram T Cells (2015) (0)
- Intratumoral Localization of Pattern Recognition Receptor Signaling Informs CAR T Cell Design (2019) (0)
- Abstract 3528: IMCmage1: A novel bi-specific biologic re-directing T cells to kill MAGE-A3/A6 presenting cancers (2012) (0)
- Sleeping Beauty (SB) Transposon Mediated Umbilical Cord Blood (UCB) T Cell Therapy for Refractory Acute Lymphoblastic Leukemia (ALL). (2006) (0)
- Glycopeptide-Specific Chimeric Antigen Receptor Targeting of T Cell Leukemia (2014) (0)
- PS1134 CHRONIC LYMPHOCYTIC LEUKEMIA CELLS IMPAIR MITOCHONDRIAL FITNESS IN T CELLS AND IMPEDE CAR T CELL EFFICACY (2019) (0)
- Cancer treatment using a chimeric receptor antigen anti-CD19 (2014) (0)
- A phase 0 exploratory study to assess the pharmacodynamic effects of single intratumoral dose of a novel bispecific targeting/immune-activating agent on the melanoma tumor microenvironment. (2011) (0)
- Hypoxia-induced reactive oxygen species contribute to immune checkpoint molecule expression in T cells undergoing rapid clonal proliferation (2018) (0)
- CTLA 4 Require CD 28 Costimulation and Are Regulated Nucleic Acid Vaccine-Induced Immune Responses (1998) (0)
- Cancer Immunity (16 May 2007) Vol. 7 Suppl.1, p. 18 (2005) (0)
- Central Memory T Cells Extensive Replicative Capacity of Human (2004) (0)
- Model Cell Differentiation from a Human Cell Line Progenitor to Dendritic + Pathways in CD 34 Evidence for Distinct Intracellular Signaling (1999) (0)
- 1238 Separating the wheat from the chaff: Engineering CARTs with superior metabolic attributes against solid tumors (2022) (0)
- Procedes de stimulation selective de la proliferation des lymphocytes t (1994) (0)
- Optimizing Adoptive T Cell Transfer (ACT) Immunotherapy For Malignant Pleural Mesothelioma (MPM) (2011) (0)
- Use of CD28 agonists to refill the T-cell tank? (2003) (0)
- That Inhibits Interleukin-2 Secretion but Allows Unique Signal to Resting Human CD4 T Cells Cutting Edge: CTLA-4 Ligation Delivers a (2013) (0)
- Transfer of influenza vaccine–primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial (2010) (0)
- T Cells Demonstrate Enhanced Specificity for CD19 + Malignancies When Stimulated with IL-21. (2008) (0)
- Durable Remissions with Control of Cytokine Release Syndrome (CRS) Using T Cells Expressing CD19 Targeted Chimeric Antigen Receptor (CAR) CTL019 to Treat Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) (2016) (0)
- Tumor-derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors. (2023) (0)
- Rapamycin-Induced Autophagy Generates Anti-Apoptotic Th1/Tc1 Cells That Mediate Increased Xenogeneic Gvhd. (2009) (0)
- CLINICAL Cardiovascular toxicity and titin cross-reactivity of af fi nity-enhanced T cells in myeloma and melanoma (2013) (0)
- Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. (2022) (0)
- Cell Proliferation T Cancer Patients Directly Inhibit Autologous Cutting Edge: Regulatory T Cells from Lung (2013) (0)
- Abstract 3798: Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells (2018) (0)
- Abstract 3139: CD33 directed chimeric antigen receptor T cell therapy as a novel regimen prior to allogeneic stem cell transplantation in acute myeloid leukemia (2015) (0)
- Preemptive T-Rapa Cell DLI after Low Intensity Allogeneic HCT May Allow for Improved Overall Survival in High Risk Lymphoid Malignancies (2016) (0)
- Abstract 3505: Preclinical testing of mRNA engineered chimeric antigen receptor T cells: Comparison of a multi-infusion protocol to a single injection of stably expressed CARs in ALL xenograft models (2012) (0)
- 510. Treating Epithelial and Metastatic Malignancies with Glycoform-Specific Chimeric Antigen Receptors (2016) (0)
- Pre-clinical development of multiplex-CRISPR-edited cell and gene therapy products (2020) (0)
- Driving cars to the clinic for solid tumors (2018) (0)
- 555. Large-Scale, Flow-Based Electroporation To Deliver Engineered Zinc Finger Protein Nucleases That Mediate High-Efficiency Disruption of the Human CCR5 Gene (2006) (0)
- Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway (2022) (0)
- A phase I/II trial of IDD-6, an autologous dendritic cell vaccine for women with advanced ovarian cancer in remission (2011) (0)
- Innovative artificial antigen presenting cells and uses thereof (2005) (0)
- Expansion of Functional Polyclonal Human T-regulatory Cell Lines Using Artificial Antigen Presenting Cells and Rapamycin. (B159) (2007) (0)
- 1108. High Rate of Anti-Tumor Immune Responses in a Phase 1 Clinical Trial of Adenoviral-Interferon-Beta Gene Transfer for Malignant Mesothelioma (MM) and Malignant Pleural Effusions (MPE) (2006) (0)
- Cell therapy for cancer – our synthetic future (2014) (0)
- Tar geting the Cancer-AssociatedTn-Glycoformof theMembraneMucinMUC 1 Control Adenocarcinoma Highlights (2016) (0)
- Abstract 4575: Correlates of clinical response following autologous stem cell transplant and adoptive immunotherapy with engineered T cells expressing an affinity-enhanced T cell receptor in patients with mutliple myeloma. (2013) (0)
- Immunoregulation recourant a la voie d'acces du cd28 (1993) (0)
- Abstract 4574: Use of CD19-targeted Chimeric Antigen Receptor-modified T (CART19) cells in ALL and CLL produce transient cytokine release syndrome (CRS), macrophage activation syndrome (MAS) and durable responses. (2013) (0)
- CAR T therapy extends its reach to autoimmune diseases (2022) (0)
- Flow cytometry in the evaluation of immune status in cancer and HIV infection. (1999) (0)
- Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL) (2018) (0)
- Role of the CD4 Receptor in Human T Lymphocyte Signalling: Effects of HIV-1 Infection on Human T Cell Activation (1989) (0)
- Use of modified T lymphocytes with chimeric antigen receptors to treat cancer (2011) (0)
- Single-Dose Intrapleural IFN-B GeneTransfer forMalignant PleuralMesotheliomaandMetastatic Pleural Effusions : HighRate ofAntitumor ImmuneResponses (2007) (0)
- Management of the Critically Ill Marrow Transplant Patient (1988) (0)
- Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation (2017) (0)
- Immune regulation on the CD28-route (1993) (0)
- Abstract 2933: Pre-clinical model of eradication of B cell leukemia with lentiviral transduced anti-CD19 chimeric immunoreceptor-modified T cells (2010) (0)
- Can't get any help? New approaches for adoptive immunotherapy of cancer. (2001) (0)
- 291 CAR T cells as a surgical adjuvant for unresectable adenocarcinoma (2022) (0)
- A Phase 1 Dose Escalation Study of Infusion of Ex Vivo CD3/CD28 Costimulated Umbilical Cord Blood-Derived T Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies (2011) (0)
- acute graft-versus-host disease but retain graft-versus-leukemia activity activated CD44hiCD8+ T cells are defective in mediating - Dendritic cell (2013) (0)
- Abstract IA10: CARs for leukemia and beyond? (2015) (0)
- Author Correction: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells (2022) (0)
- Selective killing of malignant B cells using T cells redirected against malignancy variant receptor (2014) (0)
- Addition of Deoxynucleosides Enhances Human Immunodeficiency Virus Type 1 Integration and 2LTR Formation in Resting CD4 (cid:1) T Cells (cid:1) (2007) (0)
- GENE THERAPY Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV (2013) (0)
- Keli L . Hippen with Minimal Loss of in Vivo Functional Activity ) regsMassive ex Vivo Expansion of Human Natural Regulatory T Cells ( T (2011) (0)
- Be Prevented by CTLA-4 Engagement ICOS Costimulation Requires IL-2 and Can (2001) (0)
- Identifying highly active anti-CCR4-CAR T cells for the treatment of T-cell lymphoma. (2023) (0)
- Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor (2015) (0)
- Vision: Cancer gene therapy at the crossroads (2005) (0)
- Dominant-Negative TGF- b Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication a phase I clinical trial to assess these CAR T cells as a novel approach for patients with relapsed and refractory metastatic prostate cancer (2018) (0)
- 990. Unexpected Immune Enhancement by Autologous Lentiviral Modified CD4 T Cells: Results from a Phase I Gene Transfer Trial of Lentiviral Vector-Modified T Cells Expressing Antisense Envelope (2005) (0)
- Ex Vivo Manufacture of Rapamycin-Resistant Human Th1/Tc1 Cells. (2009) (0)
- Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells (2023) (0)
- Abstract 3968: Ovarian cancer chemokine microenvironment is conducive to homing of CD3/CD28 co-stimulated T cells prepared for adoptive transfer therapy. (2013) (0)
- CART-Cell Therapies inGlioblastoma:AFirst Look (2018) (0)
- Adoptive immunotherapy with tumor-derived donor lymphocytes after allogeneic hematopoietic stem cell transplantation (2006) (0)
- 1106. Results of a Phase I Clinical Trial of Adenoviral-Interferon-Beta Gene Therapy for Malignant Mesothelioma and Malignant Pleural Effusions (2006) (0)
- Abstract B19: FAP CAR T cell therapy for solid tumors with PET imaging (2022) (0)
- Precision Immunotherapy of Cancer (2014) (0)
- Abstract IA20: Updates on CAR T Cells (2018) (0)
- Combinatorial IL13Rα2 chimeric antigen receptor-T cells plus checkpoint blockade to treat solid tumors in murine and canine models. (2017) (0)
- 335 Analyses of severe immune-mediated toxicity in patients with advanced mCRPC treated with a PSMA-targeted armored CAR T-cells (2022) (0)
- 176 Exploring the Potential of CCR5 and CXCR4 Modified CD4 T Cells to Target the HIV-1 Reservoir (2011) (0)
- Multi-Center Phase I Study of Th1/Tc1 Immunotherapy Following Autologous Hematopoietic Progenitor Cell Transplantation in Reccurrent or High Risk Plasma Cell Myeloma (2013) (0)
- IMMUNOTHERAPY IN CANCER 1 (2013) (0)
- Abstract P6-10-08: Preliminary results of a first in human Phase 1 clinical trial to demonstrate safety and feasibility of chimeric antigen receptor T (CART) cells directed against c-Met in the treatment of breast cancer (2017) (0)
- Immunotherapy with inclusion of CD28 stimulation (1989) (0)
- CD 28 co-receptor signal transduction in T-cell activation (2009) (0)
- A novel switchable car-T cell therapy for tumor retargeting and improved safety (2020) (0)
- Physicians Abstracts (2014) (0)
- Abstract PR14: Fibroblast activation protein as a universal target for chimeric antigen receptor T cell therapy in solid tumors. (2013) (0)
- Phorbol Esters Induce Differentiation of Human (1998) (0)
- Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence (2017) (0)
- Off-the-shelf CAR T cells to treat cancer (2022) (0)
- In vivo gene immunotherapy for cancer (2022) (0)
- Cancer esearch oenvironment and Immunology tiple Injections of Electroporated Autologous T Cells ressing a Chimeric Antigen Receptor Mediate R ression of Human Disseminated Tumor (2010) (0)
- Costimulated, Tumor-Derived Donor Lymphocyte (TDL) Infusion for B-Cell Tumor Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (2010) (0)
- Costimulatory Requirements for the Expansion of Human T Regulatory Cells (2008) (0)
- RENAL COMPUTED TOMOGRAPHY IS ABNORMAL IN PYELONEPHRITIS (1982) (0)
- T-Lymphocytes: Mature Polyclonal and Antigen-Specific Cell Culture (2002) (0)
- Artificial Antigen Presenting Cells (aAPC) Expanded NK-Mediated Enhanced Lysis of Allogeneic Tumor Cells Regardless of HLA Class I/KIR Mismatch and Its Implication of Use in Eradicating Acute Lymphoblastic Leukemia (ALL). (2009) (0)
- Genetically Modified T Cells for Human Gene Therapy (2007) (0)
- Pilot Clinical Trial of Adoptive Immunotherapy with Chimeric, Co-Stimulated Tumor-Infiltrating Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation. (2005) (0)
- Evaluation of the CD8+ Tumor Associated vs. Non-Tumor Associated Immune Repertoire in Cancer Patients Following Induction of Lymphopenia and Following CD3/4-1BB Based Expansion. (2005) (0)
- Schedule Dependent Effects of Adoptively Transferred Autologous T Cells After AutoSCT for Myeloma: Accelerated Immune Recovery Is Associated with Improved Event-Free Survival. (2009) (0)
- Adoptive Transfer of Autologous CD25-Depleted, CD3/CD28-Costimulated T Cells After Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma: Long-Term Follow up (2012) (0)
- A Phase II Randomized Study of HIV-Specific T-Cell GeneTherapy in Subjects with Undetectable Plasma Viremiaon Combination Antiretroviral Therapy (2002) (0)
- Oral presentations (2019) (0)
- 79 – Tumor immunology and immunotherapy (2008) (0)
- Cells: Evidence for Protein Kinase C-Mediated Hemopoietic Progenitors to Dendritic + CD34Esters Induce Differentiation of Human (2017) (0)
- Cancer immunotherapy comes of age and looks for maturity (2020) (0)
- B107 Results of a phase 1 using CCR5 Deficiency with Zinc Finger Nuclease-modified Autologous CD4 T Cells (SB-728-T) in HIV-infected Subjects (2013) (0)
- The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma (2015) (0)
- Procedes ameliores de transfection des lymphocytes t (1996) (0)
- ression of Human Disseminated Tumor (2010) (0)
- Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells (2014) (0)
- A Preclinical Model Tto Study Tumor-Infiltrating Lymphocyte (TIL) Anergy/Exhaustion In Adoptive T Cell Therapy (ACT) Of Thoracic Malignancies (2012) (0)
- 131 Genetic disruption of negative immune regulators to enhance CAR-T efficacy against solid tumors (2021) (0)
- 4-1BB is Superior to CD28 Costimulation for Generating Effector CD8+ T Cells for Adoptive Immunotherapy (48.12) (2007) (0)
- Abstract 4706: TCR engineered adoptive T-cell therapy for lung cancer is augmented by combined PD1 and TIM3 antibody blockade (2015) (0)
- COLIGATION OF CD40L (CD154) AND CD3 RESULTS IN CD4+ T CELL ACTIVATION AND THE INDUCTION OF APOPTOSIS. (1999) (0)
- Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma (2018) (0)
- NEXT GENERATION CAR T CELLS FOR LYMPHOMA AND BEYOND (2019) (0)
This paper list is powered by the following services:
Other Resources About Carl H. June
What Schools Are Affiliated With Carl H. June?
Carl H. June is affiliated with the following schools:
